Ultragenyx Pharmaceutical Inc. (53) | Business Operations (8)

Browse by Subcategory

Collaboration Agreements (7)
Services Agreements (1)

Recent Contracts

Amendment No. 11 to Collaboration and License Agreement, effective as of December 17, 2021 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 15, 2022)
Master Services Agreement, dated April 8, 2019, between Ultragenyx Pharmaceutical Inc. and Aenova Haupt Pharma Wolfratshausen GmbH (Filed With SEC on February 12, 2021)
Amendment 10 to Collaboration and License Agreement effective as of April 1, 2020 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on May 7, 2020)
Amendment No. 9 to Collaboration and License Agreement, effective December 23, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 14, 2020)
Amendment No. 8 to Collaboration and License Agreement, effective as of July 4, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin... (Filed With SEC on August 2, 2019)
Amended and Restated Collaboration and License Agreement, dated June 3, 2019, between Ultragenyx Pharmaceutical Inc. and Bayer Healthcare LLC (Filed With SEC on August 2, 2019)
Amendment No. 6 to Collaboration and License Agreement, effective as of February 1, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)
Amendment No. 7 to Collaboration and License Agreement, entered into as of December 5, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)